Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer. [electronic resource]
Producer: 20160516Description: e0134731 p. digitalISSN:- 1932-6203
- Adenocarcinoma -- drug therapy
- Adult
- Aged
- Antineoplastic Agents -- therapeutic use
- Disease-Free Survival
- Drug Resistance, Neoplasm -- drug effects
- Esophageal Neoplasms -- drug therapy
- Esophagogastric Junction -- drug effects
- Female
- Humans
- Male
- Middle Aged
- Neoplasm Metastasis
- Niacinamide -- analogs & derivatives
- Phenylurea Compounds -- therapeutic use
- Sorafenib
- Stomach Neoplasms -- drug therapy
- Survival Analysis
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.